The Gender Outcomes International Group: to Further Well-being Development (Going-fwd) Methodology on Identification and Inclusion of Gender Factors in Retrospective Cohort Studies

Valeria Raparelli Raparelli
   Universita degli Studi di Roma La Sapienza Dipartimento di Medicina Sperimentale

Colleen M. Norris
   University of Alberta Faculty of Nursing

Uri Bender
   Research Institute of the McGill University Health Centre

Maria Trinidad Herrero
   Universidad de Murcia Facultad de Medicina

Alexandra Kautzky-Willer
   Medizinische Universität Wien

Karolina Kublickiene
   Karolinska Institutet

Khaled El Emam
   University of Ottawa Faculty of Medicine

Louise Pilote (✉ louise.pilote@mcgill.ca)
   Research Institute of the McGill University Health Centre  https://orcid.org/0000-0002-6159-0628

Research

Keywords: gender, methodology, non-communicable disease, psycho-socio-cultural factors, sex

DOI: https://doi.org/10.21203/rs.3.rs-51246/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

**Background:** Gender refers to the socially constructed roles, behaviors, expressions, and identities of girls, women, boys, men, and gender diverse people. It influences self-perception, individual’s actions and interactions, as well as the distribution of power and resources in society. Gender-related factors are seldom assessed as determinants of health outcomes, despite their powerful contribution.

**Methods:** Investigators of the GOING-FWD project developed a standard methodology applicable for observational studies to retrospectively identify gender-related factors to assess their relationship to outcomes and applied this method to selected cohorts of non-communicable chronic diseases from Austria, Canada, Spain, Sweden.

**Results:** The following multistep process was applied. Step 1 (Identification of Gender-related Variables): Based on the gender framework of the Women Health Research Network (i.e. gender identity, role, relations, and institutionalized gender), and available literature for a certain disease, an optimal "wish-list" of gender-related variables/factors was created and discussed by experts. Step 2 (Definition of Outcomes): each of the cohort data dictionaries were screened for clinical and patient relevant outcomes, using the ICHOM framework. Step 3 (Building of Feasible Final List): A cross-validation between gender-related and outcome variables available per database and the “wish-list” was performed. Step 4 (Retrospective Data Harmonization): The harmonization potential of variables was evaluated. Step 5 (Definition of Data Structure and Analysis): Depending on the database data structure, the following analytic strategies were identified: (1) local analysis of data not transferable followed by a meta-analysis combining study-level estimates; (2) centrally performed federated analysis of anonymized data, with the individual-level participant data remaining on local servers; (3) synthesizing the data locally and performing a pooled analysis on the synthetic data; and (4) central analysis of pooled transferable data.

**Conclusion:** The application of the GOING-FWD systematic multistep approach can help guide investigators to analyze gender and its impact on outcomes in previously collected data.

Introduction

The distinction between sex and gender, which is clear and common in social sciences, has largely been neglected in health sciences. Indeed, sex and gender are often erroneously used and/or measured interchangeably. Given that sex and gender are not independent of each other, solely assessing one or the other cannot account for identified variations in health (1, 2). Furthermore, although the reasons explaining the increasing incidence of chronic diseases are incompletely understood, changing family, social, institutional roles, and attitudes of men and women in the last decades ultimately play a role. Thus, a wide range of behavioral factors, psychosocial processes, personal, cultural, and societal factors can create, suppress, or amplify underlying biological health differences (3, 4). While differences in health status and outcomes have been attributed to biological sex, it is now increasingly recognized that both sex and gender influence the risk of developing certain diseases, presentation of symptoms, severity of illness, response to drugs or non-pharmacological interventions, and seeking care behaviors (5). More importantly, gender may also have a bearing on people's access to and uptake of health services and the resulting health outcomes experienced throughout the life-course (6). Consequently, it is now understood that the intersectionality of gender with other social factors such as race, age, ethnicity, culture, and sexual orientation, plays a central role in an individual's health. The integration of a gender-based framework in health research is a crucial and long-awaited development (7).

When considering gender aspects in the evaluation of clinical outcomes, the first challenge for scientists originates from the apparent lack of standardized method to measure the complexities that gender encompasses. Recently, through a Pan-Canadian collaboration of a multi-disciplinary team of scientists, a comprehensive list of gender-related variables was established and collected in the setting of premature cardiovascular disease. Constructed with the aim of exploring the
impact of gender on the clinical outcomes of young patients with acute coronary syndrome, the GENESIS-PRAXY (Gender and Sex Determinants of Cardiovascular Disease: From Bench to Beyond) Gender Score (GPGS) was developed (8, 9). The GPGS measures a comprehensive group of gender-related factors and offers a pragmatic means to prospectively explore the relationships between sex, gender, and health outcomes. In patients with premature and established cardiovascular disease, gender factors, independent of biological sex, emerged as powerful predictors of the acquisition of risk factors as well as of one-year adverse health outcomes (9, 10). Most significantly, regardless of sex, patients who exhibited gender factors most traditionally ascribed to women's identity and roles in society were more likely to have a recurrent cardiac event within the first year. While these results have important direct implications for expanding the measurement of gender determinants of health to other populations, they may also identify novel determinants of health care costs that could be averted.

To facilitate the integration of sex and gender-based analyses, we developed a standard methodology that can be applied to retrospective studies for testing the associations of gender-related factors with clinical and patient-relevant outcomes.

**Methods**

The GOING-FWD (Gender Outcomes INternational Group: to Further Well-being Development), is a personalized medicine project that utilizes a big data approach. It was recently co-funded by the Canadian Institutes of Health Research, and GENDER-NET plus, which is a part of the European EU H2020 initiative (http://gender-net-plus.eu/joint-call/funded-projects/going-fwd/).

For the GOING-FWD project, around thirty accessible databases of observational studies and registries that include non-communicable chronic diseases (NCDs) among a four-country transatlantic network (i.e. Austria, Canada, Spain, Sweden) were identified. The overarching aims of the GOING-FWD project were 1) to integrate sex and gender dimensions in applied health research, and 2) to evaluate their impact on clinical cost-sensitive outcomes and patient-reported outcomes related to quality of life in NCDs including cardiovascular disease, metabolic disease, chronic kidney disease and neurodegenerative disease. Each partner of the Consortium provided the data dictionary of the retrospective cohort studies conducted in their respective countries.

The GOING-FWD Consortium is composed of investigators with multidisciplinary expertise in gender dimension, psychosocial science, computer science, epidemiology, endocrinology, internal medicine, renal and cardiovascular medicine, reproductive health, neuroscience, preclinical and clinical experimental research, health outcome research, nursing, and biostatistics. The investigators were assigned to one of the 3 work packages. The GOING-FWD methodology proposed therein is the result of the integrated activities carried out by the GOING-FWD investigators from March 2019 to December 2019. A 5-step procedure was developed that can be applied to pre-existing observational cohorts for the integration of gender-related factors in assessing their association with selected health outcomes.

GOING-FWD also has a patient partner advocate group. All interactions with patient partners are based on inclusiveness, support, mutual respect, and co-building. For example, patient partners can assist in knowledge dissemination (e.g., summer institutes, on-line educational materials, trainee journal club meetings, public forum presentations, may co-author manuscripts and provide feedback on draft manuscripts during development and participate in teleconferences. A patient partner representative also attends monthly GOING-FWD steering meetings.

Ethics approval for the project was obtained from the coordinator center at McGill University, Canada (2020-5452).

**Results**

A multistep methodology was developed as summarized in Figure 1.
**Step 1 - Identification of Gender-related Variables**

Based on the data dictionaries provided by all participating centers, a preliminary list of the gender-related factors available in selected datasets was compiled by the coordinating center. The template including the identified sex and gendered factors was presented and discussed at the first consortium meeting (Montréal, April 2019) by all investigators and stakeholders. Guided by the gender framework of the Women Health Research Network (i.e. gender identity, gender role, gender relations and institutionalized gender) (11) (Figure 2), and available literature in the four NCDs areas, the investigators created an optimal “wish list” of gender-related variables/factors: the definitions and validity of the proposed variables were discussed and expert consensus reached.

Investigators considered variables that differ between men and women in terms of prevalence and/or identified (in the published literature) as exerting different effects on the outcomes of men and women as ‘gender-related’ variables. A revised draft template including additional gendered variables was created (Table 1).

**Step 2 - Definition of Outcomes**

Each of the cohort data dictionaries were screened for outcomes of interest (including clinical/survival and patient-reported outcomes) by the coordinating center. Similar to gendered variables, a second working group was tasked with developing a list of outcome variables, using the International Consortium for Health Outcome Measurement (ICHOM) framework (12) and cost-sensitive variables and/or PROMs collected in all databases as the basic ‘outcomes variable list’. The ICHOM Standard Sets are standardized outcomes, measurement tools, time points, and risk adjustment factors for a given condition (e.g. chronic kidney disease [CKD] diabetes, etc.). Developed by a consortium of experts and patients in the field of outcomes research, the ICHOM Standard Sets focus on clinical and patient-centered outcomes. By creating a standardized list of the outcomes based on the patient’s priorities, the ICHOM framework ensures that the patient remains at the center of care (12). A pre-specified list of potential outcomes was created by all GOING-FWD investigators.

Depending on the study population and type of dataset (e.g. administrative, observational cohort study), we identified as relevant the following cost-sensitive outcomes: (a) In-patient outcomes including: in-hospital length of stay, in hospital complications and/or death and readmission within 30 days of discharge; (b) Out-patient outcomes including: access and/or numbers of visits and procedures, admissions, death, progression of disease, and disability. We also looked for the availability of any PROMs, including symptoms (e.g. pain), functioning, health related quality of life, depression, and stress. The ICHOM specific-disease outcomes were considered for each of the 4 main clinical areas of interest. The revised draft template with outcomes, compiled by the investigators, was discussed and approved by all (Table 2).

**Step 3 - Building of Feasible Final List**

The two lists were sent to each participating center to re-screen their datasets for the presence of the identified sex and gender-related and outcome variables. A cross-validation between gender-related and outcomes variables available per database was performed both locally and centrally. In case of disagreement or discordant definitions of variables among the wish-list and the actual-list, a discussion to reach consensus between coordinator center and local PI’s was performed. In principle, a more inclusive approach was pursued for both gender-related variables and outcomes definition.

After the double check of wish list and local actual list, the final feasible list of variables (core dictionary) was built and each country partner used the lists to apply to their respective research ethics boards according to the country regulations.

**Step 4 - Retrospective Data Harmonization**
Once the final list was compiled, the harmonization potential of gender-related and outcomes variable was assessed using the Maelström Research guidelines for rigorous retrospective data harmonization and merging when possible (13) (Core Dataset).

The harmonization across the different databases is a premise for assessing the feasibility of big data analysis, as well as minimizing deviations in data measurement across independently recruited databases. Data harmonization methodology consists of assessing the presence and definitions of common variables across the different databases, followed by the creation of a harmonized dataset and subsequent extraction of information from study-specific datasets into the harmonized dataset. For example, while many datasets may record smoking status, the exact definition of this variable may differ between datasets: one may define this variable as dichotomous, others may quantify the number of cigarettes smoked by the participant. Through data harmonization, a new variable definition is created to include the information from each of these datasets, which in this case would be reduced to smoking status as a dichotomous variable. Throughout this process, harmonized definitions that are created are scrutinized until a consensus is reached.

Step 5 - Definition of Data Structure

Beyond harmonization, the structure and country specific management of health data was recognized as crucial to planning and conducting the final analysis addressing the relationships between the gender-related factors. The analysis plans for each country will be based on the following options: 1) if data is not transferable even when anonymized - study-specific data analyses will be done locally followed by a meta-analysis combining study-level estimates; 2) for multiple cohorts in different countries, analyses will be done centrally, but the individual-level participant data will remain on local servers using a federated analysis approach; 3) the local data is synthesized and then a pooled analysis of the synthesized data is performed, or 4) if the data is transferable: data will be pooled and analyzed at a central location (Figure 3).

Discussion

The GOING-FWD methodology is a multistep process that provides insights on how to incorporate a measure of gender-related factors when variables have already been collected. The Big Data paradigm shift is significantly transforming healthcare and biomedical research (14). Massive volumes of aggregated biomedical data often display different levels of granularity fostering the capability to explore, on large international scales, the effect of variables such as gender and/or sex. Big data allows researchers to overcome sample size issues and perform types of analysis such as interaction or mediation that would not be feasible and reliable in small cohorts/studies. Nevertheless, there are some important issues related to data privacy and the merging of different databases when a cross-country comparison is planned, especially where issues on General Data Protection Regulation (GDPR) need to be addressed in detail.

Strengths

The GOING-FWD framework is a feasible methodology to foster the assessment of the gender impact on outcomes in retrospective studies. The screening of each dataset is a step that not only allows to identify the gender-related variables but also provides the rationale for selecting psycho-social factors that could be collected prospectively in the same cohort. The effort of investigating how sex and gender-related factors impact clinical and patient-related outcomes in NCDs is essential as it provides evidence for sex- and gender-tailored interventions.

We have learned that a multidisciplinary team is a prerequisite for developing such methodology including gender-experts and patient partners. Patients with lived experience can contribute to understanding what is really important for a specific disease which further strengthens the concept of patient empowerment in clinical practice.
The international nature of GOING-FWD methodology highlights important considerations on the complexity of gender. Gender norms, identities, and relations vary by culture, historical era, ethnicity, socioeconomic status, geographic location, and other factors. We expect that the gender behaviours and attitudes captured by our variables may differ among women, men, and gender-diverse individuals as well as between these groups. Gender norms also change overtime and across countries. Therefore, as researchers, we need to recognize its dynamic nature when we integrate gender in clinical research questions.

We also envisioned our multi-country analyses as an opportunity to capture institutional gender by including some country specific variables that are commonly available like the Gender Inequality Index (GII) developed by the United Nations Development Programme (UNDP) (15). The GII is a composite measure to quantify gender inequality within a country and measures opportunity costs, reproductive health empowerment, and labor market participation. Another similar measure of gender is the European Institute for Gender Equality (EIGE)'s Gender Equality Index, which includes additional details about country specific domains of health, violence against women, work, money, knowledge time and power (16). The idea is to re-look and re-think on how we can gain the most from data on gender that are already available.

Finally, the GOING-FWD approach is timely and might foster inclusion of gender in understanding the 2019 coronavirus disease (COVID-19) pandemic. In fact, the global COVID-19 economic and medical crisis could be the first outbreak where sex and gender differences are recorded and taken into account by researchers and policy makers. The GOING-FWD methodology will be instrumental in exploring the impact of various gender domains on outcomes across countries.

**Challenges**

In developing the GOING-FWD methodology, we have faced practical challenges. Firstly, the lack of a standardized definition of gender-related factors is perceived as an obstacle to researchers even if they are interested in the topic. The low availability of gender-related factors in retrospective studies is not surprising but this should not preclude analyses. We strongly encourage clinical and even preclinical researchers to start from what they have even if only one gender-related factor is available. Merging more datasets allows us to perform analyses that incorporate interaction and mediation given large sample sizes. Secondly, in the current era, data accessibility and data protection issues in international networks can represent a deal-breaker in pursuing this kind of research approach. Increasingly strict data protection regulations in many jurisdictions limit the ability to share sensitive health information. This requires the application of privacy enhancing technologies to enable the necessary analyses to be performed without the transfer of personal health information. Finally, harmonization is a necessary step to allow big data analysis, but it is a time-consuming process and susceptible to pitfalls related to the quality of the process and difficulties of maintenance when several databases from different countries are merged. Personnel with explicit knowledge and skills are required to perform data harmonization from both technical (i.e. computing science, mathematics) and clinical (i.e. life science) perspectives.

We believe that our example of a derived “wish list” based on selected variables offers a standardized tool that can be widely used to explore the consistency of associations with health behaviours and outcomes.

**Perspective and Significance**

The GOING-FWD Consortium, a multidisciplinary network of Canadians and European researchers and patient-partners, provides a framework that will support clinical researchers in integrating gender relevant factors in their research questions when using already collected databases hence providing solutions for the challenges that such approach poses.

**Conclusions**
The application of a systematic multistep approach defining gender-related variables, the use of data harmonization and country specific data structure models, inform the identification and inclusion of gender factors in retrospective cohort studies. Gleaning important information on gender will not only strengthen current clinical practice but will also provide a stepping stone for sex and gender - tailored interventions and care.

Declarations

**Ethics approval and consent to participate:** “Not applicable”

**Consent for publication:** “Not applicable”

**Availability of data and materials:** “Not applicable”

**Competing Interests:** All Authors have read and understood the BMJ Group policy on declaration of interests and declare the following interests: none (VR, CNM, UB, MTH, AK, KK, and LP); Dr K. El Emam is co-founder, director, and investor in Replica Analytics Ltd, a CHEO Research Institute / University of Ottawa spinoff company that develops data synthesis software.

**Funding:** The GOING-FWD Consortium is funded by the GENDER-NET Plus ERA-NET Initiative (Project Ref. Number: GNP-78): The Canadian Institutes of Health Research (GNP-161904), La Caixa Foundation (LCF/PR/DE18/52010001), The Swedish Research Council (2018-00932) and The Austrian Science Fund (FWF, I 4209). VR is funded by the Scientific Independence of Young Researcher Program of the Italian Ministry of University, Education and Research (RBSI14HNVT).

**Authors’ contributions:** V.R.: conception, design, interpretation of data, drafting of the manuscript and revision; C.M.N.: conception, design, interpretation of data, critical revision; U.B.: acquisition and analysis; M.T.H., design, interpretation of data, revision of the draft; A.K.: design, interpretation of data, revision of the draft; K.K.: design, interpretation of data, revision of the draft; K.E.E.: analysis and development of new IT solution, synthetic data; L.P.: conception, design, interpretation of data, drafting of the manuscript and revision; GOING-FWD Consortium: design contribution, acquisition of data and revision of the draft. All authors read and approved the final manuscript.

Acknowledgements

**Group author: GOING-FWD Collaborators**

**Co-Principal Investigators**

Louise Pilote; McGill University Health Center and McGill University, Canada

Colleen Norris; University of Alberta, Canada

Valeria Raparelli; Sapienza University of Rome, Italy

**Site Principal Investigators**

Alexandra Kautzky-Willer; Medical University of Vienna, Austria

Karolina Kubickiene; Karolinska Institutet, Sweden

Maria Trinidad Herrero; Universidad de Murcia, Spain

**Co-Investigators**
Karin Humphries; University of British Columbia, Canada
Monica Parry; Lawrence S. Bloomberg Faculty of Nursing, Canada
Ruth Sapir-Pichhadze; McGill University Health Center and McGill University, Canada
Michal Abrahamowicz; McGill University Health Center and McGill University, Canada
Khaled El Emam; University of Ottawa, Canada
Simon Bacon; Concordia University, Canada
Peter Klimek; Medical University of Vienna, Austria

Scientific Advisory Committee
Vera Regitz-Zagrosek; Charité – Universitätsmedizin Berlin, Germany
Londa Schiebinger; Stanford University, USA
Carole Claire; University of Lausanne, Switzerland
Rachel Dryer; Yale University, USA

Trainees
Christina Tadiri; McGill University Health Center and McGill University, Canada
Zahra Azizi; McGill University Health Center and McGill University, Canada
Uri Bender; McGill University Health Center and McGill University, Canada
Sabeena Jalal; McGill University Health Center and McGill University, Canada
Salima Hemani; Lawrence S. Bloomberg Faculty of Nursing, Canada
Heather Burnside; Lawrence S. Bloomberg Faculty of Nursing, Canada
Carola Deschinger; Medical University of Vienna, Austria
Juergen Harreiter; Medical University of Vienna, Austria
Teresa Gisinger; Medical University of Vienna, Austria
Giulia Tosti; Sapienza University of Rome, Italy
Claudia Tucci; Sapienza University of Rome, Italy
Giulio Francesco Romiti; Sapienza University of Rome, Italy
Ange Laucyte-Cibulskiene; Karolinska Institutet, Sweden
Liam Ward; Karolinska Institutet, Sweden
Raquel Gomez De Leon; Universidad de Murcia, Spain
Ana Maria Lucas; Universidad de Murcia, Spain

Patient Partners

Donna Hart; Ontario, Canada

Nicole Hartman/Nickerson; Nova Scotia, Canada

Angie Fullerton/MacCaul; PEI, Canada

Jeanette Smith; Ontario, Canada

Myra Lefkowitz; Ontario, Canada

Ann Keir; BC, Canada

Kyle Warkentin (caregiver); BC, Canada

Rachael Manion; Ontario, Canada

References

1. CIHR. Online Training Modules: Integrating Sex & Gender in Health Research: CIHR; 2019 [updated 10-09-2019].
   https://cihr-irsc.gc.ca/e/49347.html.

2. Norris CM, Murray JW, Triplett LS, et al. Gender roles in persistent sex differences in health-related quality-of-life outcomes of patients with coronary artery disease. *Gend Med.* 2010;7(4):330-9.

3. Weber AM, Cislaghi B, Meausoone V, et al. Gender norms and health: insights from global survey data. *Lancet.* 2019;393(10189):2455-68.

4. Forouzanfar MH, Alexander L, Anderson HR, et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet.* 2015;386(10010):2287-323.

5. Bartz D, Chitnis T, Kaiser UB, et al. Clinical Advances in Sex- and Gender-Informed Medicine to Improve the Health of All: A Review. *JAMA Intern Med.* 2020.

6. Vaidya V, Partha G, Karmakar M. Gender differences in utilization of preventive care services in the United States. *J Womens Health (Larchmt).* 2012;21(2):140-5.

7. Tannenbaum C, Ellis RP, Eyssel F, et al. Sex and gender analysis improves science and engineering. *Nature.* 2019;575(7781):137-46.

8. Pelletier R, Ditto B, Pilote L. A composite measure of gender and its association with risk factors in patients with premature acute coronary syndrome. *Psychosom Med.* 2015;77(5):517-26.

9. Pelletier R, Khan NA, Cox J, et al. Sex Versus Gender-Related Characteristics: Which Predicts Outcome After Acute Coronary Syndrome in the Young? *J Am Coll Cardiol.* 2016;67(2):127-35.

10. Norris CM, Johnson NL, Hardwicke-Brown E, et al. The Contribution of Gender to Apparent Sex Differences in Health Status Among Patients with Coronary Artery Disease. *J Womens Health (Larchmt).* 2017;26(1):50-7.

11. Johnson JL, Greaves L, Repta R. Better science with sex and gender: Facilitating the use of a sex and gender-based analysis in health research. *Int J Equity Health.* 2009;8:14.

12. ICHOM. Standard- Sets: Start measuring outcomes that matter most to patients. 2020 [23/04/2020]. Available from: https://www.ichom.org/.
13. Fortier I, Raina P, Van den Heuvel ER, et al. Maelstrom Research guidelines for rigorous retrospective data harmonization. *Int J Epidemiol.* 2017;46(1):103-5.

14. Obermeyer Z, Emanuel EJ. Predicting the Future - Big Data, Machine Learning, and Clinical Medicine. *N Engl J Med.* 2016;375(13):1216-9.

15. Gender Inequality Index (GII) 2020 [23/04/2020]. Available from: [http://hdr.undp.org/en/content/gender-inequality-index-gii](http://hdr.undp.org/en/content/gender-inequality-index-gii).

16. Gender Equality Index: European Institute for Gender Equality; 2020 [updated 2019]. Available from: [https://eige.europa.eu/gender-equality-index/2019](https://eige.europa.eu/gender-equality-index/2019).

**Tables**

**Table 1. GOING-FWD Cohorts Gender Related Variables – Wish List**
| Roles                                              | Institutionalized Gender                      |
|---------------------------------------------------|-----------------------------------------------|
| Primary earner status                             | Educational Level                             |
| Employment Status                                 | SES/Income                                    |
| Occupation                                         | Monthly finances                              |
| Paid Work hours per week                          | Income (personal, household)                  |
| Unpaid work hours per week (e.g. care giver hours)| Number of persons living in household         |
| Full/part time work                               | Retirement eligibilities                      |
| Child caregiver responsibilities The individual or others | Perceived Social Standing Questionnaire (e.g. McArthur Scale) |
| Adult caregiver responsibilities                   | GII (Gender inequality index) Questionnaire    |
| Number of hours per week spent on housework       | Maternity Paternity related variables         |
| Status of household’s primary responsibility      | Discrimination                                |
| Number of children                                 | Day-to-day experiences                        |
| Relations                                          | Perceived bias                                |
| Marital/Relationship Status                        | Stigmatization                                |
| Family or local network (social capital)           | Violence (hx or present)                      |
| Social support                                     | Intimate partner domestic                     |
| Social support (any recognized social support instrument) | Ethnic violence                              |
| Availability of Caretaker (for self)              | Sexual orientation                            |
| Identity                                           | Immigration Status                            |
| Stress                                             | Behavioral/Lifestyle Risk Factors             |
| 14-Item Perceived stress scale                    | European Health Determinants Module           |
| Stress level at work (any measure of stress)      | Current smoking, Smoking history, Cigarettes per day |
| Stress level at home (any measure of stress)      | Physical activity                             |
| Stress management                                  | Physical activity (e.g. self-reported: PPAQ) - Physical activity (e.g. accelerometer) |
| Personality traits                                 | Food diary - Diet quality index               |
| Emotional intelligence Questionnaire              | Alcohol consumption                           |
| Any validated measures of personality (NEO classic 5 personality traits) | Substance use (Use of drugs)                   |
| BSRI (instrument) measurement of gender identity  | Nutrition                                     |
| Depressive symptomatology/Anxiety                 | Overall diet quality index                    |
| Patient Health Questionnaire-9                    | Physical activity barriers (fatigue, lack of motivation, etc.) |
| HAD Scale - Hospital Anxiety and Depression Scale | Nutrition barriers (expensiveness, lack of motivation, etc.) |
|-------------------------------------------------|----------------------------------------------------------|
| Anxiety/Depression any scale                     | Physical activity facilitators (social support, self-motivation, etc.) |
| Childhood trauma (reported history)              | Nutrition facilitators (social support, self-motivation, etc.) |

**Abbreviations:** BSRI – Bem Sex-Role Inventory; HAD – Hospital Anxiety and Depression Scale; SES – socioeconomic status; GII – gender inequality index; hx – history; PPAQ – Pregnancy Physical Activity Questionnaire.

**Table 2 GOING-FWD Cost-sensitive and Patient-Relevant Outcomes Measures – Wish List**
| Condition                  | Survival          | Acute Complications                 | Patient Reported Health Status | Disease Progression | Disease Specific Outcomes | Medications               |
|---------------------------|-------------------|-------------------------------------|--------------------------------|---------------------|---------------------------|---------------------------|
| Acute Coronary Syndrome   | All-cause mortality | Major procedural complications       | SAQ-7, PHQ-2                  | Revascularization   | MI, HF, Stroke            | Beta-blockers, ACEi/ARB, Atatin, Anti-platelet |
| Heart Failure             | All-cause mortality | Treatment side effects/ complications | KCCQ                          | Hospitalization     |                           | Beta-blockers, ACEi/ARB, MRAs, ARNi |
| Stroke                    | All-cause mortality | Intra-cranial hemorrhage            | Cognitive function, Motor function, Social function, PROMIS SF v1.1 Global Health | Hospitalization     | Stroke recurrence         |                           |
| Dementia                  | All-cause mortality |                                      | NPI, MoCA, EQ-5D, Bristol Activity Daily Living Scale, QoL-AD, Quality of Wellbeing Scale | Clinical Dementia Rating, Hospitalization, Falls |                           |                           |
| Parkinson's               | All-cause mortality | Parkinson's Disease Quality of Life Questionnaire (PDQ-8) | Hospitalization | Falls |                           |                           |
| Multiple Sclerosis        | All-cause mortality | Relapse, Motor/sensory function     |                                 | Hospitalization     | Micro-vascular complications |                           |
| Endocrine/Diabetes        | All-cause mortality | Ketoacidosis, Hypo/hyperglycemia    | WHO-5, PAID, PHQ-9             | Physician visits    | Hospitalization            |                            |
| Chronic Kidney            | All-cause         | Access bleeding                      | SF-12 or 12, Hospitalization   | Hospitalization     | CV events: HF, stroke, MI, PAD, Activated vitamin D |
| Disease                        | mortality                     | Access                      | SF-36                  | eGFR                       | Peritoneal dialysis modality survival/vascular access survival | Erythropoietin |
|-------------------------------|-------------------------------|-----------------------------|------------------------|---------------------------|-----------------------------------------------------------------|----------------|
| Access hematoma               |                               | Access infection            | PROMIS-Global Health   | Transplant                | Dialysis                                                        | Calcitonin    |
| Line sepsis                   |                               | Catheter-related infections | PROMIS-29              | Dialysis                  | Microalbuminuria                                                 | phosphate binders |
| Herniation/effusion           |                               |                             | EQ-5D-L                | Kidney Failure Risk Index | Stage 5                                                         | Potassium binders |

**Abbreviations**

- **SAQ-7** – Seattle Angina Questionnaire-7; **PHQ-2** – Public Health Questionnaire-2; **MI** – myocardial infarction; **HF** – heart failure; **ACEi** – angiotensin converting enzyme inhibitors; **ARB** – angiotensin II receptor blockers; **KCCQ** – Kansas City Cardiomyopathy Questionnaire; **MRA** – mineralcorticoid receptor antagonist; **ARNi** – angiotensin receptor-neprilysin inhibitors; **PROMIS-SF** - Patient-Reported Outcomes Measurement Information System Short Form; **NPI** – NeuroPsychiatric Inventory; **MoCA** – Montreal Cognitive Assessment; **EQ-5D** – European Quality of Life questionnaire-5D; **QoL-AD** – Quality of Life-Alzheimer's Disease questionnaire; **PDQ-8** – Parkinson's Disease Questionnaire-8; **WHO-5** - The World Health Organization-Five Well-Being Index; **PAID** – Problem Areas in Diabetes questionnaire; **PHQ-9** – Patient Health Questionnaire-9; **SF-12/16** – 12/16 item Short Form survey; **PROMIS-Global Health** - Patient-Reported Outcomes Measurement Information System; **eGFR** – estimated glomerular filtration rate; **CV** – cardiovascular; **PAD** – peripheral arterial disease; **PGI** – Patient Global Impression scales.

**Figures**
Figure 1: The GOING-FWD Multistep Methodology on Identification and Inclusion of Gender Factors in Retrospective Cohort Studies

Figure 1

The GOING-FWD Multistep Methodology on Identification and Inclusion of Gender Factors in Retrospective Cohort Studies.

Figure 2. Domains that gender encompasses

Figure 2
Domains that gender encompasses.

Figure 3  Data Structure and Potential Options for Analysis based on Transferability of Data

Data Structure and Potential Options for Analysis based on Transferability of Data.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- CoverLetter27July2020OSSD.pdf